Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00905450 · ClinicalTrials.gov registry record · Phase 2
Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery
A Phase 2 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 415
- Enrollment target
NCT00905450 is a Phase 2 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 415 participants.
The verdict
NCT00905450, a Phase 2 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 415 participants
- Enrollment target
Study Summary
This clinical study is being conducted to identify the most effective drug concentration and dose frequency of BOL-303242-X (Mapracorat) ophthalmic suspension, for the treatment of inflammation following cataract surgery.
Interventions
- DRUG BOL-303242-X
- DRUG Vehicle for BOL-303242-X
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 415 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00905450
The ClinicalTrials.gov registry entry for NCT00905450 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 415 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BOL-303242-X is the first listed.
NCT00905450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00905450 about?
NCT00905450 is a clinical study titled "Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery". This clinical study is being conducted to identify the most effective drug concentration and dose frequency of BOL-303242-X (Mapracorat) ophthalmic suspension, for the treatment of inflammation following cataract surgery.
What is the current status of trial NCT00905450?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 415 participants. The study started on 2009-06. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00905450?
The interventions under investigation include: BOL-303242-X (DRUG), Vehicle for BOL-303242-X (DRUG).
Who is sponsoring clinical trial NCT00905450?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.